11-Sep-2026
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards Program
Business Wire (Thu, 10-Sep 7:00 AM ET)
Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors
Business Wire (Wed, 9-Sep 8:00 AM ET)
Business Wire (Mon, 24-Aug 6:30 PM ET)
Alkermes plc Reports Second Quarter 2026 Financial Results
Business Wire (Tue, 28-Jul 7:00 AM ET)
Alkermes to Report Second Quarter Financial Results on July 28, 2026
Business Wire (Tue, 14-Jul 4:00 PM ET)
Business Wire (Mon, 13-Jul 7:00 AM ET)
Business Wire (Wed, 17-Jun 4:15 PM ET)
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
Business Wire (Mon, 15-Jun 7:00 AM ET)
Market Chameleon (Wed, 12-Nov 2:58 AM ET)
ALKS Takes the Initiative: Alkermes Revealed as Offeror in Avadel Takeover Position Disclosure
Market Chameleon (Wed, 5-Nov 5:40 AM ET)
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Alkermes PLC - trades on the NASDAQ stock market under the symbol ALKS.
As of September 11, 2026, ALKS stock price declined to $45.97 with 1,170,749 million shares trading.
ALKS has a beta of 0.10, meaning it tends to be less sensitive to market movements. ALKS has a correlation of 0.00 to the broad based SPY ETF.
ALKS has a market cap of $7.71 billion. This is considered a Mid Cap stock.
Last quarter Alkermes PLC - reported $496 million in Revenue and $.00 earnings per share. This beat revenue expectation by $39 million and missed earnings estimates by -$.14.
In the last 3 years, ALKS traded as high as $55.67 and as low as $22.01.
The top ETF exchange traded funds that ALKS belongs to (by Net Assets): VTI, VB, VBK, XBI, VXF.
ALKS has outperformed the market in the last year with a return of +65.9%, while the SPY ETF gained +17.4%. However, in the most recent history, ALKS shares have underperformed the stock market with its stock returning +2.3% in the last 3 month period and -3.0% for the last 2 week period, while SPY has returned +3.9% and -0.7%, respectively.
ALKS support price is $45.16 and resistance is $47.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALKS shares will trade within this expected range on the day.
